首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   15817篇
  免费   748篇
  国内免费   375篇
耳鼻咽喉   35篇
儿科学   146篇
妇产科学   299篇
基础医学   1979篇
口腔科学   247篇
临床医学   1042篇
内科学   2094篇
皮肤病学   217篇
神经病学   858篇
特种医学   265篇
外国民族医学   6篇
外科学   761篇
综合类   2390篇
现状与发展   1篇
预防医学   760篇
眼科学   225篇
药学   3501篇
  6篇
中国医学   1330篇
肿瘤学   778篇
  2023年   208篇
  2022年   323篇
  2021年   571篇
  2020年   642篇
  2019年   471篇
  2018年   398篇
  2017年   629篇
  2016年   648篇
  2015年   579篇
  2014年   1401篇
  2013年   2140篇
  2012年   1782篇
  2011年   1578篇
  2010年   1157篇
  2009年   942篇
  2008年   784篇
  2007年   405篇
  2006年   360篇
  2005年   332篇
  2004年   264篇
  2003年   182篇
  2002年   132篇
  2001年   55篇
  2000年   37篇
  1999年   26篇
  1998年   47篇
  1997年   39篇
  1996年   36篇
  1995年   28篇
  1994年   15篇
  1993年   14篇
  1992年   9篇
  1990年   17篇
  1989年   11篇
  1988年   15篇
  1987年   13篇
  1986年   8篇
  1985年   64篇
  1984年   77篇
  1983年   87篇
  1982年   85篇
  1981年   55篇
  1980年   58篇
  1979年   42篇
  1978年   36篇
  1977年   28篇
  1976年   23篇
  1975年   24篇
  1974年   20篇
  1973年   24篇
排序方式: 共有10000条查询结果,搜索用时 302 毫秒
991.
目的 探讨核转录因子-κB(NF-κB)及肿瘤坏死因子-α(TNF-α)在大鼠肺血管内巨噬细胞(PIM)内的表达及吡咯醛二硫氨基甲酸(PDTC)对其表达的影响.方法 SD大鼠随机分4组:对照组、PDTC对照组、CCI4组、CCI4+PDTC组.取动脉血作血气分析,静脉血测内毒素和肝功能.取肠系膜淋巴结作细菌培养.应用免疫组化方法 观察PIM的粘附、聚集情况,以及TNF-α和NF-κB的蛋白表达和定位.非放射性凝胶电泳阻滞实验(EMSA)检测NF-κB活性,SYBR Green I实时定量PCR方法 检测肺组织中TNF-α的mRNA表达.结果 CCl4组发展成肝肺综合征(HPS)模型,表现为PaO2、PaCO2降低和肺泡一动脉血氧分压(A-aDO2)升高,肝功能异常,内毒素血症.CCl4组肠系膜淋巴结培养阳性率为62.5%(5/8),与CCl4+PDTC组的66.7%(6/9)比较差异无统计学意义(P>0.05).CCl4组超过10个巨噬细胞的血管为60.8%(292/480),而CCl4+PDTC组仅为19.6%(106/540),两组比较差异有统计学意义(P<0.01).对照组和PDTC对照组中肺血管内无巨噬细胞聚集.免疫组化染色NF-κB和TNF-α蛋白均在CCl4组的PIM中表达.CCl4组的NF-κB活性和TNF-α的mRNA表达明显高于对照组、PDTC对照组和CCl4+PDTC组(均P<0.05).结论 NF-κB诱导PIM内TNF-α表达在HPS中发挥重要作用,PDTC通过抑制PIM中NF-κB的活性,降低PIM活性以及其中TNF-α表达,从而改善HPS.  相似文献   
992.
精制人白细胞α-干扰素治疗妇科宫颈糜烂4133例,I°1794例,治愈率85.45%,有效率98.22%;Ⅱ°2143例,治愈率79.61%,有效率93.23%;Ⅲ°196例,治愈率35.71%,有效率53.06%。α-干扰素对轻度及中度糜烂疗效显著,对重度疗效较差。α-干扰素对轻度及中度疗效与冷冻、激光、微波、电的术疗效无显著差异,且副作用少,对重度糜烂采用α-干扰素和冷冻联合治疗疗效明显。  相似文献   
993.
Resveratrol has been shown recently to exhibit antimetastatic effect on various human solid tumors. However, the possible molecular mechanism for its antimetastatic action needs to be elucidated. In this study, we investigated the effect of resveratrol on metastasis potential of colon carcinoma cells under normoxia and hypoxia in vitro. These results showed that, resveratrol can restrict the migration, adhesion, invasion and MMP-9 and MMP-2 secretion in Lovo cells cultured under normoxia and hypoxia. Hypoxia and iron chelator 2,2′-dipyridyl treatment can stimulate the invasion and migration enhancement of Lovo cells, while resveratrol exhibited substantial resistance on the metastasis potential stimulation by inhibiting the mRNA expression of VEGF and MMP-9 in colon carcinoma cells under normoxia and hypoxia, reducing HIF-1α protein expression under hypoxia. Also, iron chelator 2,2′-dipyridyl treatment showed approximately the same effect on metastasis potential as Lovo cells cultured under hypoxia. These data demonstrated that, the antimetastatic effect of resveratrol under hypoxia were associated with the restriction of HIF-1α protein expression and stabilization, which could be a promising drug target for resveratrol in the development of an effective chemopreventive and anticancer therapy in human tumors.  相似文献   
994.

Background

GPR56/ADGRG1 is a member of the adhesion-class G protein-coupled receptor (aGPCR) family important in brain development, oncogenesis and tumor metastasis. Like other aGPCRs, GPR56 is cleaved at the GPCR proteolysis site (GPS) motif into an N-terminal fragment (NTF) and a C-terminal fragment (CTF). Existence of soluble GPR56 (sGPR56) has been shown in vitro, however the underlying mechanism and its pathophysiologic role remains undetermined.

Objective

To assess the presence of sGPR56 in human serum using ELISA assay and compare the serum sGPR56 levels among patients of various chronic inflammatory diseases and healthy subjects.

Patients and methods

In this study, serum samples from patients with systemic lupus erythematosus (SLE) (n = 57), rheumatoid arthritis (RA) (n = 95), Sjögren's syndrome (SS) (n = 29), ankylosing spondylitis (AS) (n = 51), and normal controls (n = 81) were analyzed using sGPR56-specific ELISA.

Result

We show that serum sGPR56 levels are increased in patients of RA, but not in those with SLE, SS and AS. Intriguingly, serum sGPR56 levels in RA patients correlated with positive rheumatoid factor, a marker of bone erosion and poor outcome. In addition, an elevated sGPR56 level is also noted in RA patients with higher tumor necrosis factor level.

Conclusion

we conclude that sGPR56 is present in vivo and sGPR56 level is elevated in certain chronic inflammatory diseases such as RA. Hence, sGPR56 might be considered a potential biomarker for RA disease progression.  相似文献   
995.
996.
997.
998.
999.
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a frequent and severe chronic disease drastically impairing life quality. The underlying pathomechanism is incompletely understood yet but there is convincing evidence that in at least a subset of patients ME/CFS has an autoimmune etiology. In this review, we will discuss current autoimmune aspects for ME/CFS. Immune dysregulation in ME/CFS has been frequently described including changes in cytokine profiles and immunoglobulin levels, T- and B-cell phenotype and a decrease of natural killer cell cytotoxicity. Moreover, autoantibodies against various antigens including neurotransmitter receptors have been recently identified in ME/CFS individuals by several groups. Consistently, clinical trials from Norway have shown that B-cell depletion with rituximab results in clinical benefits in about half of ME/CFS patients. Furthermore, recent studies have provided evidence for severe metabolic disturbances presumably mediated by serum autoantibodies in ME/CFS. Therefore, further efforts are required to delineate the role of autoantibodies in the onset and pathomechanisms of ME/CFS in order to better understand and properly treat this disease.  相似文献   
1000.
α_1-抗胰蛋白酶活性测定方法及其影响因素的研究   总被引:1,自引:2,他引:1  
目的研究用发色底物法测定α1-AT生物活性时,以正常人混合血浆为参考标准的血浆稀释度范围和测定的影响因素。方法采用酶标仪测定抗胰蛋白酶与过量的胰蛋白酶反应后,剩余的胰蛋白酶与BAPNA发色反应的OD值(405nm),观察时间和温度对反应的影响,优化正常人混合血浆(30人份)稀释度范围,建立并验证血浆标准曲线,同时观察几种物质对测定的影响。结果通过优化实验,血浆的稀释倍数在1/50~1/100之间有良好的线性;PEG4000、蔗糖、Tween80/TNBP(S/D)、辛酸钠等对活性测定无明显影响,而枸橼酸钠浓度>0.125mol/L,α1-AT生物活性测定结果偏高约20%。结论以正常人混合血浆为参考标准品,用酶标仪测定α1-AT的生物活性,快速、准确,方法稳定可靠,α1-AT制备过程中常用的几种物质,除枸橼酸钠外,对其活性测定均无影响。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号